Study of Efficacy and Safety of LOU064 in Inadequately Controlled Asthma Patients
Status:
Terminated
Trial end date:
2020-04-27
Target enrollment:
Participant gender:
Summary
This was a proof-of-concept study to evaluate the efficacy of LOU064 in patients with
inadequately controlled asthma. All subjects were randomized with 3:2 ratio to receive LOU064
100 mg once daily or LOU064 matching placebo for 12 weeks with standard background therapy of
budesonide 80 µg/formoterol 4.5 µg two inhalations twice a day (b.i.d).